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Summary
The growth factor receptors expressed on endothelial cells are of special interest because of their
potential to program endothelial cell growth and differentiation during development and
neovascularization in various pathological states, such as wound healing and angiogenesis associated
with tumorigenesis. Vascular endothelial growth factor (VVEGF) also known as vascular permeability
factor) is a potent mitogen and permeability factor, which has been suggested to play a role
in embryonic and tumor angiogenesis. The newly cloned FLT4 receptor tyrosine kinase gene
encodes a protein related to the VEGF receptors FLT1 and KDR/FLK-1. We have here studied
the expression ofFLT4 and the other two members of this receptor family in human fetal tissues
by Northern and in situ hybridization. These results were also compared with the sites ofexpression
of VEGF and the related placenta growth factor (PIGF) . Our results reveal FLT4 mRNA expression
in vascular endothelial cellsin developing vessels of several organs. A comparison of FLT4, FLT1
and KDR/FLK-1 receptor mRNA signals shows overlapping, but distinct expression patterns
in the tissues studied. Certain endothelia lack one or two of the three receptor mRNAs. These
data suggest that the receptor tyrosine kinases encoded by the FLT gene family may have distinct
functions in the regulation of the growth/differentiation of blood vessels.
Rceptor tyrosine kinases (RTKs)t play a major role in
the growth and differentiation of various cell types
during development and in adult organisms. The intrinsic
tyrosine kinase function of RTKs is activated upon binding
of growth factors with diverse biological activities (1). Of
special interest are growth factor receptors regulating the
proliferation of blood vessels, which are necessary for the
normal growth and development of many tissues and an in-
tegral part of the development of all organs in multicellular
organisms. Two different mechanisms are involved in the for-
mation ofblood vessels, namely vasculogenesis, the develop-
ment ofblood vessels from in situ differentiating endothelial
cells, and angiogenesis, the sprouting ofcapillaries from preex-
isting vessels (2, 3). Vasculogenesis may be unique to em-
bryonic development, whereas angiogenesis can occur during
the entire life span in both physiological and pathological
1 Abbreviations used in this paper: PDGFR, platelet-derived growth factor
receptor; PIGF, placenta growth factor; RTK, receptor tyrosine kinase;
VEGF, vascular endothelial growth factor; vWF, von Willebrand factor.
processes and is essential for e.g., reproduction, woundhealing,
and tumorigenesis. Common to the various processes of an-
giogenesis is the pattern of response of endothelial cells to
angiogenic stimuli, which include a number of known growth
factors (4, 5).
The vascular endothelial growth factor (VEGF) is a po-
tent direct acting endothelial cell mitogen with angiogenic
activity (6-8). The expression pattern of VEGF in embryonic
tissues suggests that it may induce the growth of capillaries
into tissues during mouse development (9). It has been shown
that VEGF is also expressed in macrophages and in prolifer-
ating epidermal keratinocytes, as well as in several types of
tumor cells, e.g., in glioblastomas (10-14). Thus VEGF may
be involved in tumor angiogenesis and in the healing of skin
wounds. As VEGF has been shown to increase capillary per-
meability and to stimulate migration ofmonocytes across the
endothelial cell monolayer, if may also beresponsible for tissue
edema associated with inflammation (15-17). The VEGF-
related placenta growth factor (PIGF) has not been found in
other tissues besides placenta (18, 19).
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genes encode endothelial cell receptors for VEGF (20-24).
The related fms-like tyrosine kinase-4 (FLT4) cDNA was
cloned from a human erythroleukemia cell cDNA library (25,
26) and from a human placental cDNA library (27, 28). The
FLT gene family belongs to the class III RTKs (1), which
also includes two protooncogenes (cfms and c-kit), the cx
and 0 chains of platelet-derived growth factor receptors
(PDGFR) and the product ofthe FLT3/FLK2 gene. Recently,
FLT4 has also been cloned from quail (29), and KDR from
mouse (designated FLK-1), rat, and quail (29, 30-32). The
FLT4, FLTI, and KDR RTKs differ from other members
of class III RTKs by having seven instead offive Ig-like loops
in their extracellular domains. Thus they constitute a novel
subfamily of class III tyrosine kinases.
The FLT4 gene maps to the long arm of chromosome 5,
where many growth factor and growth factor receptor genes,
including PDGFRB, FMS, FGFR4, and FGFA are known
to be located (25, 27, 33). In analysis of RNA isolated from
human adult tissues FLT4 mRNA was found to be expressed
in placenta, lung, kidney, heart, and liver in a decreasing order
(25). FLT4 transcripts were also detected in most fetal tissues
studied (26). We have here analyzed FLT4 mRNA in human
fetal tissues by Northern and in situ hybridization and com-
pared the expression pattern to those of FLT1 and KDR
receptor genes, VEGF, and to the endothelial cell marker von
Willebrandfactor (vWF) (34). Our results show FLT4 mRNA
in vascular endothelial cells in developing vessels. Distinct,
but partially overlapping patterns of expression of the three
receptors are found in various endothelia.
Materials and Methods
Tissues.
￿
Tissues from 17- and 20-wk-old human fetuses were
obtained from legal abortions induced with prostaglandins. The
study was approved by the Ethical Committee of the Helsinki
University Central Hospital. The gestational age was estimated
from the fetal foot length (35). The fetal tissues were fixed with
4% paraformaldehyde for about 20 h before dehydration and paraffin
embedding.
Northern Analysis.
￿
As templates for hybridization probes we
used the inserts of the FLT1 (20), KDR (23), VEGF (8), PIGF
(18), and vWF (36) cDNA plasmids and a 2.5-kb insert of FLT4
cDNA, encoding the extracellular domain of the receptor (26).
These were labeled by the random priming method and hybridized
to a multiple tissue Northern blot (Clontech, Palo Alto, CA), con-
taining 2 tcg of poly(A)* RNA from several human fetal tissues.
Hybridization was carried out in 50% formamide, 5 x Denhardt's
solution (100x Denhardt's solution is 2% Ficoll, polyvinylpyrroli-
done, and BSA), 5x SSPE (3 M NaCl, 200 mM NaH2PO,-H20,
20 mM EDTA, pH 7.0), 0.1% SDS, and 0.1 mg/ml of sonicated
salmon sperm DNA at 42°C for 18-24 h. The filter was washed
in standard conditions in 2x SSC (300 mM sodium chloride, 30
mM sodium citrate) containing 0.05% SDS for 15 min followed
bywashes in 1x SSC/0.1% SDS and exposed to Kodak XAR5 film.
In Situ Hybridization.
￿
The FLT4 cDNA probes (antisense and
sense) were synthesized from linearized pGEM-3Z(f+) plasmid
(Promega Corp., Madison, WI), containing a SacI fragment from
the 5' end of the FLT4 cDNA (nucleotides 55-207) (26), using
T7 and SP6 polymerases and ['SSJUTP (Amersham Corp., Arling-
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ton Heights, IL). The FLTI cRNA probe was generated by sub-
cloning an Aval-SacI fragment (nucleotides 706-2310) (20) into
pGEM-3Z(f+). For KDR, an EcoRl-HindIII fragment covering
base pairs 6-715 of the region coding for the extracellular part of
the receptor was used (23). The VEGF probe was an EcoRl frag-
ment containing base pairs 57-638 of the cDNA (8) cloned in
different orientations for sense and antisense RNA synthesis. The
PIGF probe was an EcoRl fragment containingbase pairs304-944
in pGEM-3Z(f+) (18) and the vWF probe was an EcoRl-HindlII
fragment covering base pairs 1-2334 (36).
In situ hybridization of tissue sections was performed according
to Wilkinson et 21. (37, 38) with the following modifications: (a)
instead of toluene, xylene was used before embedding in paraffin
wax; (b) 6-Am sections were cut, placed on a layer ofdiethyl pyrocar-
bonate-treated water on the surface of glassslides pretreatedwith
2% 2-aminopropyltriethoxysilane; (c) alkalinehydrolysiswas omitted
for the FLT4 probe; (d) the hybridization mixture contained 50%
deionized formamide; (e) the high stringency wash was for 90 min
at 65°C in a solution containing 30 mM DTT and Ix SSC. The
sections were covered with NTB-2 emulsion (Eastman Kodak Co.,
Rochester, NY) and stored at 4°C. The slides were exposed for
2-8 wk, developed, and stained with hematoxylin. Control hybridi-
zations with sense strand and RNase A-treated sections did not
give a specific signal above background.
Results
Analysis of FLT Receptor VEGF, and PIGF mRNAs in
Human Fetal Tissues. For comparative studies ofFLT4, FLT1,
and KDR expression in human fetal tissues, a Northern blot
containing polyadenylated RNA from fetal heart, brain, lung,
liver, and kidney was hybridized with labeled cDNA inserts
ofplasmids representing each one of the three genes. Probes
from the extracellular domains of the receptors were used
in order to minimize crosshybridization, as these regions show
only about 30% nucleic acid sequence homology with one
another (26). The resulting autoradiograms are shown in
Fig. 1.
As can be seen from Fig. 1, the FLT4 gene is expressed
in fetal lung, kidney, heart, and liver as a more abundant 5.8-kb
mRNA and a minor 4.5-kb mRNA, that had a stable ratio
in the different samples. These two mRNAs differ in their
3' regions as a result of differential RNA splicing and encode
COOH-terminal-distinct polypeptides (39). However, they
share the same 5' sequences, including the region of the probe.
The FLTI gene is expressed as three mRNAs of about 8.0,
7.5, and 3.0 kb. The shortest mRNA form cannot be de-
tected using probes from the region of cDNA encoding the
cytoplasmic domain, and thus it is likely to represent a splicing
variant encoding a truncated extracellular form of the receptor
(20). When compared to the distribution of the FLT4 mRNA,
the FLT1 mRNA is more abundant in the brain and heart
samples. The KDR probe detects a single mRNA band of
7.0 kb. This is distributed similarly to the FLT4 mRNA,
except that a definitive KDR mRNA band can be seen also
in the brain sample. From the Northern hybridization results
it can be concluded that each one of the three receptors is
expressed at high levels in fetal lung, kidney, and heart, and
less in brain and liver.
Strikingly, the expression pattern of the three receptorsFigure 1 .
￿
Analysis ofFLT receptor, VEGF, and PLGFmRNAs in human
fetal tissues. A Northern blot containing polyadenylated RNA from the
indicated tissues of human fetuses was hybridized with the gene-specific
cDNA fragments used as templates for cRNA synthesis for the in situ
hybridization . The sizes of the transcripts are shown.
parallels the expression of the VEGF gene . Abundant 3.7
and 4.5 kb mRNA signals for VEGF are seen in the lung,
kidney, and heart RNA, and none in the brain or liver at
this time of development (Fig. 1) . In contrast, weak signals
were obtained for the PIGF mRNA from the liver, heart,
lung, and kidney. ThemRNA of the endothelial cell marker
vWF was abundant only in the lung and heart samples and
was considerably weaker in the brain . Surprisingly, no ex-
pression was detected in the kidney .
In Situ Hybridization Analysis ofHuman Fetal Lung.
￿
In the
present and previous Northern blotting analysis, abundant
FLT4mRNA was found in human fetal and adult lungs . Lung
tissue was therefore chosen for the first in situ hybridization
analysis with the FLT4 cRNA probe. Comparisonwasmade
with the FLT1 and KDR mRNAs, which also are highly
expressed in the lung . Fig. 2 shows the darkfield and lightfield
photographs of lung tissue from a 17-wk-old human fetus
hybridized with the three probes .
As seen in Fig. 2,A and B, theFLT4 signal decorates mainly
the borders of interlobular septa and groups of cells in the
connective tissuebetween the lobuli, whereas only little specific
hybridization signal is obtained in the lung parenchyma .
Proliferation of the mesenchyme occurs in human lung be-
tween the 16th and 26th weeks of gestation, and during this
period a rich blood supply develops within the mesenchyme
(40, 41) . The pattern and distribution of the FLT4 mRNA
signal as well as its comparison with the hybridization signal
ofVWF mRNA (Fig. 2, A and B andj and K) suggest that
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these cells are endothelial cells, although their definitive or-
ganization into a continuous endothelium of a vessel cannot
be discerned even at higher magnification (Fig. 2 C) . How-
ever, many preformed endothelia ofVWF positive vessels in
the lung parenchyma were negative for FLT4 . The FLT4
mRNA signal in the interlobular septa appears to be more
prominent than the signal for VWF (compare Fig. 2, A and
J) . This may depend on a difference in the timing of max-
imal expression of the two mRNAs, which has been shown
in a comparison with VWF and tek, a novel endothelial RTK
(42) . Control hybridization with the FLT4 sense probe is
shown in Fig . 2F . No specific signal can be detected, despite
a prolonged exposure of this in situ autoradiograph.
In contrast to FLT4, FLTI expression was seen primarily
in lung parenchyma, mainly in-between the primitive respi-
ratory bronchioles and alveolar ducts (Fig. 2,D andE) . Most
of this signal apparently comes from endothelial cells in de-
veloping capillaries (arrowheads), which also are positive for
VWFmRNA (Fig. 2,J andK) . In addition, as pointed out
by the open arrows, certain large vessels in the interlobular
septa are positive for FLT1 .
Of the three genes, the strongest hybridization signals were
obtained for KDR (Fig. 2, G) . The distribution ofKDR
mRNA overlapped with those ofFLT4 andFLTI . A similar
spotlike hybridization pattern was obtained in the lung pa-
renchyma as with the FLT1 probe (Fig. 2, D and G), but
a more continuous pattern was detected in the capillaries of
interlobular septae. Control sense probes for FLT1 andKDR
gave also negative results (data not shown) . For comparison,
the mRNA for VEGF, which is the ligand for these two
receptors (22-24), was expressed in the epithelia ofprimitive
respiratory bronchioles and alveolar ducts (Fig . 2, L and n .
This agrees with the data of Berse et al. (10), who reported
VEGF expression in rat lung alveolar epithelial cells.
FLT Receptor mRNA Expression in the Fetal Heart.
￿
Figs .
3 and 4 show that FLT4, FLn, andKDR hybridization results
in the fetal heart and comparison withVWF . The epicardium
consists of a thin superficial layer of simple squamous epithe-
lial cells overlying a layer of connective tissue containing small
blood and lymphatic vessels and nerve fibers. Deeper in this
layer are larger blood vessels, such as the coronaries (43) . FLT4
mRNA was present in a spotlike pattern in the epicardium ;
also few small epicardial vessels were positive (arrows, Fig .
3, A and B) . However, no association of this signal with the
major coronary vessels was seen. BothFLT1 andKDR were
expressed in many smaller vessels in the epicardium (arrows
in Fig. 3, C and E) . Interestingly, FLT1mRNA was present
also in the coronary endothelium (Fig . 3, open arrows), whereas
KDRmRNA was not . Themyocardial capillaries were nega-
tive for FLT4, although the myocardium appears pale in Fig .
3 A because ofsome unspecific background and overexposure
of the photomicrograph . In contrast, the FLT1 and KDR
probes decorated small capillaries in the myocardium (arrow-
heads, Fig. 3, C,D and E, F, respectively) . The VWF probe
gave a strong signal from both epicardial and myocardial vessels,
suggesting that its mRNA is more abundant than the receptor
mRNAs investigated (Fig . 1, G and H) .
In the endocardium, equally interesting differences wereFigure 2 .
￿
Localization of FLT4, FLT1, KDR, and VEGF transcripts in lung tissue of a 17-wk-old human fetus. Shown are darkfield and lightfield
photomicrographs ofin situ autoradiograms. Note that FLT4 (A-C) is mainly expressed in endothelial cells of interlobular septae in a spotlike pattern
(arrows) . FLTI andKDR expression is found in lung tissue (arrowheads, D, E and G, H, respectively) and in the vessels in between the lobuli (open
arrows) . Hybridization with the sense probe is shown in (F) . VEGF transcripts are seen in the epithelial cells of the primitive respiratory bronchioles
and alveolar ducts (I and L) . Control hybridization with the vWF probe is shown (J and K) . Scale bar, 100 Am.
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￿
Expression of FLT4, FLTI, andKDR in fetal heart . FM mRNA is expressed in a spotlike pattern in certain endothelial cells of the
epicardium (A and B) . Arrows indicate some FLT4 positive epicardial vessels (A) . FLTI and KDR probes decorate small myocardial (" capillaries
(arrowheads, C, D and E, F, respectively). FLTI transcripts are also seen in the endothelium of coronary vessels (CV) (open arrows, C and D) . Both
FLT1 and KDR expression is detected in many smaller vessels in the epicardium (arrows, C and E) . (Ep) Epicardium. The VWF control is shown (C
and H) . Scale bar, 100 um .
seen in the expression patterns ofthe three receptormRNAs .
NoFMmRNA was detected in the endocardial cells (Fig .
4, A and B) . FLTI was present predominantly in the in-
tramyocardial capillaries (Fig . 4, arrowheads), and hybridized
weakly in a spotlike manner in the endocardial cells (arrows
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in Fig. 4, C and D), whereas more abundant amounts ofKDR
mRNA and high amounts ofVWFmRNA were expressed
both in the endocardial cells and in the myocardial capillaries
(Fig. 4, E-H) .
In Situ Analysis ofFetal Kidney.
￿
FLT4 gave a weak, but2082
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Figure 4.
￿
mRNA expression infetal en-
docardium . No FLT4expression is detected
(A and B) . FLTI is expressed predominantly
in the myocardial capillaries (arrowheads,C
and D), and in some endocardial (Ec) cells
(arrows) . KDR is expressed more abundantly
both in the endocardium (arrows, E and F)
and in the myocardial capillaries (arrowheads,
E and F) . VWF expression is shown as a
control (G and H) . Scale bar, 100 p.m .Figure 5.
￿
Expression of FLT4, FLT1, KDR, and VEGF transcripts in fetal kidney. FLT4 is expressed weakly in several glomeruli (arrows) and in
cells interspersed in the mesenchymal tissue ofthe cortical region ofthe kidney (A andB). Strong FLT1 mRNA expression is detected in the glomerular
endothelial cells (arrows,C and D) . KDR is found in the glomerulal endothelium in the more medullary part ofthekidney (arrows,E and F) . Hybridiza-
tion with the sense probe is shown (G) . VEGF rnRNA is present in the glomerular epithelial cells (arrows, H and 1) . Scale bar, 100 p.m.
definite signal in several glomeruli in the cortex (Fig . 5, arrows)
and in cells interspersed in the mesenchymal tissue of the cor-
tical region of the kidney (Fig. 5, A and B) . Strong FLT1
expression was seen in the glomerular endothelial cells (Fig.
5, C and D) and some in the peritubular capillaries in the
medullary parts (data not shown), whereasKDR was specific
to the endothelium of glomerular capillaries in the more
medullary regions of the kidney cortex (Fig. 5, E and F) .
No specific signal was evident with the sense probe (Fig. 5
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G) . Also, as reported previously for adult rats (10), VEGF
mRNA was produced by the glomerular epithelial cells (Fig.
5, H and 1) .
Analysis ofFetalMesenterium and Gut.
￿
Fig . 6 shows a com-
parison ofreceptor expression in the mesenterium . The mesen-
terium carries the blood supply to and from the gut . In addi-
tion, it contains abundant lymphatic vessels . In tissue sections,
the blood vessels frequently contained remaining RBC, which
gave a false positive reflection of light in darkfield micros-Figure 6 .
￿
Localization of transcripts in fetal mesenterium . Hybridization with sense probe (A and B) shows a false positive reflection of light due
to RBC (arrowheads, A-F) . Strong FLT4 (arrows, C and D) andKDR (arrows, G and H) expression is found in most vessels of the mesenterium . In
contrast, no FLTY expression is detected (E and F) . Scale bar, 100 Ftm .
copy even in sections hybridized with the sense probe (ar-
￿
A comparison of the distribution of these three receptor
rowheads in Fig . 6, A-F) . Interestingly, strong FLT4 (Fig.
￿
mRNAs in the gut (Fig. 7) shows also distinct differences.
6, C and D) andKDR (Fig. 6, G andM signals were present
￿
FLT4 is positive only in a few endothelial cells in the sub-
in most vessels of the mesenterium (arrows), whereas FLTI
￿
mucosal (S) layer (Fig . 7, A and B) . FLTI is strongly positive
appeared negative in these sections (Fig. 6, E and F) .
￿
in the endothelium of small vessels extending to the intes-
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forKDR mRNA (Fig . 7, E and F), which is present both
in the submucosa and in the capillaries of the villi (arrows) .
Discussion
Our results revealed distinct but overlapping patterns of
expression ofthree RTK genes of theFLT family in thehuman
fetus . The results showed that the FLT4 mRNA, like the
FLT1 and KDR mRNAs, is expressed in certain endothelia .
The wide distribution of all three mRNAs in the different
organs suggests that these growth receptors have general and
important roles in endothelial cell growth and/or differen-
tiation.
Our Northern hybridization results indicated similar pat-
terns ofdistribution of the three receptor mRNAs in major
fetal tissues . The highly vascularized tissues, lung, kidney,
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Figure 7 .
￿
FLT4, FLT1, and KDR, mRNA in
fetal gut . FLT4 expression is detectedonlyin some
interspersed endothelial cells (inset,A) and in small
vessels in the submucosal layer (arrows,A and B) .
FLTI is expressed in the endothelium ofcapillaries
extending into the intestinal villi (arrows, C and
D) .KDRmRNA is present both in the submucosa
and in the capillaries of the villi (arrows,E and F) .
(V) villi ; (S) submucosa ; (111) mucosa . Scale bar,
100 i4m.
and heart had the highest levels ofall three receptor mRNAs.
However, lower amounts of these mRNAs are widely dis-
tributed, as shown by previous Northern blotting and hy-
bridization analyses ofmany fetal and adult tissues (20, 25,
26, 28, 30-32) . Furthermore, like the receptormRNAs, VEGF
mRNA was also highly expressed in the lung, kidney, and
heart, whereas small amounts of PlGFmRNA were mainly
expressed in the heart and liver. Our previous data have indi-
cated that abundant PlGF mRNA is present in placental tissue
(19) and apparently the amounts are much smaller in fetal
tissues .
Interestingly, our in situ hybridization studies revealed differ-
ences in the expression patterns of the three RTK mRNAs
in all tissues . A good example of the differences was seen in
endocardial cells, where no FLT4mRNA could be detected,
but a few cells showed positivity for FLT1mRNA andKDR
mRNA was expressed quite prominently . According to a re-cent report (29) the avian homologies of FLT4 and KDR,
Quek2 and Quekl, respectively, are expressed in endothelial
cells during early development. In a 9-d quail embryo, these
genes are switched off in various compartments of the vas-
cular network. For example, the endocardium, except for the
cardiac valves, becomes negative for Quek2 and Quekl . Of
particularinterest is that the genes are not switched off simul-
taneously in the same endothelial cells (29). Also, FLT1 and
FLK1 mRNA expression differ from each other during mouse
development. Both receptors are expressed in endothelial cells
during earlydevelopment. During the fetal period (E14-E16.5)
FLT1 is undetectable, whereas KDR mRNA continue to be
expressed in all endothelia (24, 44). In adult mice, the FLT1
receptor mRNA is again detected in endothelia.
The origin of the endothelial cells of the glomerulus and
the mode of development of the kidney vasculature have been
controversial subjects for a century. Most likely, a pair of vessels
sprout from the dorsal aorta and invade the metanephric
blastema in a close association with the ingrowing ureteric
bud. When the latter branches and induces pretubular ag-
gregates around its tips, the migrating endothelial cells follow
the border between these condensated areas and the stroma.
When the S-shaped bodies are formed, this directs the en-
dothelial cells into the developing glomerulus (45). FLT4 signal
from the cells interspersed in the upper mesenchyme are most
probably derived from endothelial cells, this being in agree-
ment with the model of development of the kidney vascula-
ture. However, no vWF could be detected in the kidney. It
thus seems that all three receptors are early markers of en-
dothelial cells. In addition, FLK-1/KDR mRNA expression
has been detected in fetal liver cells of 12-day mouse embryos,
which are enriched for hematopoietic stem cells, and in the
mesodermal layer of the yolk sac (24, 31) . Also, FLT4 is ex-
pressed in undifferentiated teratocarcinoma cells, and down-
regulated upon their induced differentiation (26). All three
receptors of this class are also expressed in cultured human
leukemia cell lines in vitro (unpublished data of Pertovaara,
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